Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
Their findings could prove to be a breakthrough in not only treating tumors, but ensuring cancer doesn’t return years later — giving peace of mind to patients that their illness is truly gone.
“Not all cancer cells are the same, even in the same tumor,” said Dr. William Taylor, a professor in the Department of Biological Sciences in the UToledo College of Natural Sciences and Mathematics. “There is a lot of variability and some of the cells, like cancer stem cells, are much nastier. Everyone is trying to figure out how to kill them, and this may be one way to do it.”
Taylor and Dr. L.M. Viranga Tillekeratne, a professor in the Department of Medicinal and Biological Chemistry in the UToledo College of Pharmacy and Pharmaceutical Sciences, reported their findings in a paper recently published in the journal Scientific Reports.
Cancer stem cells are an intriguing target for researchers because of their potential to re-seed tumors.
When doctors remove a tumor surgically or target it with chemotherapy drugs or radiation therapy, the cancer may appear to be gone. However, evidence suggests that a tiny subpopulation of adaptable cancer cells can remain and circulate through the body to seed new metastasis in far-off locations.
Those cancer stem cells, Taylor said, are similar to dandelions in a well-manicured lawn.
“You could chop the plant off, but it will drop a seed. You know the seeds are there, but they’re hiding,” he said. “You pull one weed out and another comes up right after it. Cancers can be like this as well.”
The small molecule they have isolated appears to lock on to those stem cells and kill them by blocking their absorption of an amino acid called cystine.
UToledo was awarded a patent for the discovery late last year.
For Tillekeratne and Taylor, uncovering a new class of therapeutic molecules could prove to be an even larger contribution to cancer research than the project they initially envisioned.
“At present, there are no drugs that can kill cancer stem cells, but people are looking for them,” Tillekeratne said. “A lot of drugs are discovered by serendipity. Sometimes in research if you get unexpected results, you welcome that because it opens up a new line of research. This also shows the beauty of collaboration. I wouldn’t have been able to do this on my own, and [Taylor] wouldn’t have been able to do it on his own.”
Tillekeratne has received a three-year, $449,000 grant from the National Institutes of Health National Cancer Institute to continue testing the effectiveness of the newly identified therapy.
Because the molecules so selectively target cancer stem cells, it’s possible they could ultimately be paired with other chemotherapy drugs to deliver a more comprehensive treatment.
However, the researchers have found their agents show stand-alone promise in treating sarcomas and a subtype of breast cancer known as claudin-low breast cancer, which represents up to 14 percent of all breast cancers and can be particularly difficult to treat.
The Latest on: Cancer-killing agents
via Google News
The Latest on: Cancer-killing agents
- Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy ...on April 12, 2021 at 1:02 pm
These were significantly greater than that seen with single agent anti-PD1, and were further enhanced ... proprietary therapeutics intended to improve the direct cancer-killing effects of selective ...
- Cancer-killing virus shows promise for inoperable skin tumourson April 12, 2021 at 2:53 am
A treatment based on a common-cold virus has shown promise for inoperable skin tumours. Surgery is the main treatment for melanoma, the deadliest form of skin cancer. In advanced cases where the ...
- Cancer-killing treatment using a common cold virus offers hope to patients with inoperable tumorson April 10, 2021 at 9:19 pm
A new study using one of the viruses responsible for the common cold has shown promise in treating advanced skin cancer that could not be treated with surgery. The results of the Phase 1 study ...
- Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancerson April 9, 2021 at 9:43 am
NEW YORK, April 9, 2021 /PRNewswire/ -- Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors ...
- PICTURED: The Ecuadorian sisters, aged 3 and 5, who were rescued by US border agents after being dropped over 14-ft high border wall in New Mexicoon April 2, 2021 at 1:39 pm
Cristo Rey, near El Paso, on Tuesday night. The girls were rescued by agents soon after and taken to the Santa Teresa Border Patrol Station for medical evaluation. In a photo obtained by Fox ...
- NK Disruptor GT Biopharma Advances Liquid and Solid Tumor Cancer TriKEs in Clinical Developmenton March 30, 2021 at 1:36 am
Additionally, TriKE™ has the unique ability to be a self-sustaining, self-activating, target-directed NK cell therapeutic agent – resulting ... and enhance the cancer killing abilities of ...
- Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeuticson March 25, 2021 at 8:22 am
PORT-1 delivers potent cancer-killing agents directly into the tumor, immediately reducing cancer burden, breaking down the cytokine wall, and recruiting immune cells to attack residual disease.
- Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excesson March 15, 2021 at 4:33 am
“Cortisol activity blunts the cancer-killing attributes of immunotherapeutic agents such as checkpoint inhibitors,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer, “which may be why ...
- Analysis: Buyers return but Dubai real estate faces long road to recoveryon March 15, 2021 at 4:30 am
Yet market activity has picked up in the last six months, after lockdowns and curfews were lifted, estate agents say, helping to stabilise prices for family villas and high-end beach and golf ...
- The Evolution of Cancer Researchon September 22, 2020 at 6:42 pm
“Being adaptable is the main advantage of immuno-oncology agents over other cancer therapies ... In essence, ADCs combine a cancer-killing payload and an antibody that binds to a specific ...
via Bing News